- $1.39bn
- $1.48bn
- $53.04m
U.S. STOCKS ON THE MOVE-Gold miners, Tesla, ADM
AnaptysBio slumps after abandoning eczema drug development
AnaptysBio to abandon eczema drug development after mid-stage trial failure (updated)
AnaptysBio to abandon eczema drug development after mid-stage trial failure (updated)
Brief: Anaptys Announces Phase 2B Trial Of ANB032, A BTLA Agonist, Did Not Meet Endpoints
AnaptysBio abandons eczema drug development after mid-stage trial failure
AnaptysBio Inc expected to post a loss of $1.59 a share - Earnings Preview
U.S. RESEARCH ROUNDUP-Apollo, Booking Holdings, Portillos
Brief: AnaptysBio Q3 Net Income USD -32.851 Million
U.S. STOCKS ON THE MOVE-Zimmer Biomet, Shake Shack, Microsoft
U.S. STOCKS ON THE MOVE-XPO, Blueprint Medicines, AbbVie
AnaptysBio plunges as Eli Lilly drops co's arthritis drug from pipeline
U.S. RESEARCH ROUNDUP-Amgen, Atkore, Moneylion
U.S. RESEARCH ROUNDUP- Actinium Pharmaceuticals, Albemarle, ArcBest
AnaptysBio Inc reports results for the quarter ended in June - Earnings Summary
Brief: AnaptysBio Q2 Net Income USD -46.66 Million
AnaptysBio Inc expected to post a loss of 89 cents a share - Earnings Preview
U.S. RESEARCH ROUNDUP-Anaptysbio, Blackstone, Netflix
U.S. RESEARCH ROUNDUP- Altus Power, Jack in the Box, Home Depot